SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK.

Laurell, AAS; Venkataraman, AV; Schmidt, T; Montagnese, M; Mueller, C; Stewart, R; Lewis, J; Mundell, C; Isaacs, JD; Krishnan, MS; et al. Laurell, AAS; Venkataraman, AV; Schmidt, T; Montagnese, M; Mueller, C; Stewart, R; Lewis, J; Mundell, C; Isaacs, JD; Krishnan, MS; Barber, R; Rittman, T; Underwood, BR (2024) Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK. Br J Psychiatry, 224 (Special Issue 6). pp. 198-204. ISSN 1472-1465 https://doi.org/10.1192/bjp.2023.166
SGUL Authors: Isaacs, Jeremy

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (365kB) | Preview

Abstract

BACKGROUND: Phase three trials of the monoclonal antibodies lecanemab and donanemab, which target brain amyloid, have reported statistically significant differences in clinical end-points in early Alzheimer's disease. These drugs are already in use in some countries and are going through the regulatory approval process for use in the UK. Concerns have been raised about the ability of healthcare systems, including those in the UK, to deliver these treatments, considering the resources required for their administration and monitoring. AIMS: To estimate the scale of real-world demand for monoclonal antibodies for Alzheimer's disease in the UK. METHOD: We used anonymised patient record databases from two National Health Service trusts for the year 2019 to collect clinical, demographic, cognitive and neuroimaging data for these cohorts. Eligibility for treatment was assessed using the inclusion criteria from the clinical trials of donanemab and lecanemab, with consideration given to diagnosis, cognitive performance, cerebrovascular disease and willingness to receive treatment. RESULTS: We examined the records of 82 386 people referred to services covering around 2.2 million people. After applying the trial criteria, we estimate that a maximum of 906 people per year would start treatment with monoclonal antibodies in the two services, equating to 30 200 people if extrapolated nationally. CONCLUSIONS: Monoclonal antibody treatments for Alzheimer's disease are likely to present a significant challenge for healthcare services to deliver in terms of the neuroimaging and treatment delivery. The data provided here allows health services to understand the potential demand and plan accordingly.

Item Type: Article
Additional Information: © The Author(s), 2024. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/ licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Keywords: Dementias/neurodegenerative diseases, mental health services, other imaging, out-patient treatment, pharmaceutical drug trial, Dementias/neurodegenerative diseases, mental health services, pharmaceutical drug trial, out-patient treatment, other imaging, 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences, Psychiatry
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Br J Psychiatry
ISSN: 1472-1465
Language: eng
Dates:
DateEvent
June 2024Published
18 January 2024Published Online
23 November 2023Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
NIHR203312National Institute for Health and Care Researchhttp://dx.doi.org/10.13039/501100000272
MR/W014386Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR-VO49879/1UK Prevention Research PartnershipUNSPECIFIED
PubMed ID: 38235531
Web of Science ID: WOS:001144353200001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/116095
Publisher's version: https://doi.org/10.1192/bjp.2023.166

Actions (login required)

Edit Item Edit Item